RBC Capital Reiterates Outperform Rating on Insmed (INSM), 'Literature Analysis Suggests TPIP Has A High Likelihood of Meaningful Activity'
Tweet Send to a Friend
RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $100.00 price target on Insmed (NASDAQ: INSM).The analyst commented: "Given ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
